APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Angiogenesis Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Angiogenesis Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchCancer Angiogenesis Inhibitors Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Angiogenesis Inhibitors Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cancer Angiogenesis Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Angiogenesis Inhibitors Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Angiogenesis Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Cancer Angiogenesis Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Angiogenesis Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Angiogenesis Inhibitors include Novartis, Neumedicines, Marsala Biotech, Mabtech, Levolta Pharmaceuticals, Kyowa Hakko Kirin, Intas Pharmaceuticals, ImClone Systems and Hetero Drugs, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Angiogenesis Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Angiogenesis Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Angiogenesis Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Angiogenesis Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Angiogenesis Inhibitors Segment by Company

Novartis

Neumedicines

Marsala Biotech

Mabtech

Levolta Pharmaceuticals

Kyowa Hakko Kirin

Intas Pharmaceuticals

ImClone Systems

Hetero Drugs

Genexine

Genentech

Fuji Film Kyowa Kirin Biologics

Five Prime Therapeutics

Cancer Angiogenesis Inhibitors Segment by Type

Oncogene Targeted Therapy

Matrix Degrading & Remodeling Targeted Therapy

VEGF Targeted Therapy

FGF Targeted Therapies

Others

Cancer Angiogenesis Inhibitors Segment by Application

Ocular Neovascularization

Interferon Alpha-2α

Cancer

Cancer Angiogenesis Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Angiogenesis Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Angiogenesis Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Angiogenesis Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Angiogenesis Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Angiogenesis Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Angiogenesis Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Angiogenesis Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Angiogenesis Inhibitors Industry Trends Table 2. Cancer Angiogenesis Inhibitors Industry Drivers Table 3. Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges Table 4. Cancer Angiogenesis Inhibitors Industry Restraints Table 5. Global Cancer Angiogenesis Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Angiogenesis Inhibitors Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Cancer Angiogenesis Inhibitors Sales Market Share by Manufacturers Table 9. Global Cancer Angiogenesis Inhibitors Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Cancer Angiogenesis Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Angiogenesis Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Angiogenesis Inhibitors Manufacturers, Product Type & Application Table 13. Global Cancer Angiogenesis Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Angiogenesis Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oncogene Targeted Therapy Table 17. Major Manufacturers of Matrix Degrading & Remodeling Targeted Therapy Table 18. Major Manufacturers of VEGF Targeted Therapy Table 19. Major Manufacturers of FGF Targeted Therapies Table 20. Major Manufacturers of Others Table 21. Global Cancer Angiogenesis Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2026) & (k units) Table 23. Global Cancer Angiogenesis Inhibitors Sales by Type (2027-2032) & (k units) Table 24. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2026) Table 25. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2027-2032) Table 26. Global Cancer Angiogenesis Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Cancer Angiogenesis Inhibitors Revenue by Type (2021-2026) & (k units) Table 28. Global Cancer Angiogenesis Inhibitors Revenue by Type (2027-2032) & (k units) Table 29. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2026) Table 30. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Ocular Neovascularization Table 32. Major Manufacturers of Interferon Alpha-2α Table 33. Major Manufacturers of Cancer Table 34. Global Cancer Angiogenesis Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2026) & (k units) Table 36. Global Cancer Angiogenesis Inhibitors Sales by Application (2027-2032) & (k units) Table 37. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2026) Table 38. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2027-2032) Table 39. Global Cancer Angiogenesis Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Cancer Angiogenesis Inhibitors Revenue by Application (2021-2026) & (k units) Table 41. Global Cancer Angiogenesis Inhibitors Revenue by Application (2027-2032) & (k units) Table 42. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2026) Table 43. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2027-2032) Table 44. Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2026) & (k units) Table 46. Global Cancer Angiogenesis Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global Cancer Angiogenesis Inhibitors Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Cancer Angiogenesis Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 51. North America Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 52. Europe Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 54. Europe Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2027-2032) & (k units) Table 61. Global Cancer Angiogenesis Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Cancer Angiogenesis Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Cancer Angiogenesis Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2021-2026) Table 65. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2027-2032) Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis Cancer Angiogenesis Inhibitors Product Portfolio Table 70. Novartis Recent Development Table 71. Neumedicines Company Information Table 72. Neumedicines Business Overview Table 73. Neumedicines Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio Table 75. Neumedicines Recent Development Table 76. Marsala Biotech Company Information Table 77. Marsala Biotech Business Overview Table 78. Marsala Biotech Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio Table 80. Marsala Biotech Recent Development Table 81. Mabtech Company Information Table 82. Mabtech Business Overview Table 83. Mabtech Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Mabtech Cancer Angiogenesis Inhibitors Product Portfolio Table 85. Mabtech Recent Development Table 86. Levolta Pharmaceuticals Company Information Table 87. Levolta Pharmaceuticals Business Overview Table 88. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio Table 90. Levolta Pharmaceuticals Recent Development Table 91. Kyowa Hakko Kirin Company Information Table 92. Kyowa Hakko Kirin Business Overview Table 93. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio Table 95. Kyowa Hakko Kirin Recent Development Table 96. Intas Pharmaceuticals Company Information Table 97. Intas Pharmaceuticals Business Overview Table 98. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio Table 100. Intas Pharmaceuticals Recent Development Table 101. ImClone Systems Company Information Table 102. ImClone Systems Business Overview Table 103. ImClone Systems Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio Table 105. ImClone Systems Recent Development Table 106. Hetero Drugs Company Information Table 107. Hetero Drugs Business Overview Table 108. Hetero Drugs Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio Table 110. Hetero Drugs Recent Development Table 111. Genexine Company Information Table 112. Genexine Business Overview Table 113. Genexine Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Genexine Cancer Angiogenesis Inhibitors Product Portfolio Table 115. Genexine Recent Development Table 116. Genentech Company Information Table 117. Genentech Business Overview Table 118. Genentech Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Genentech Cancer Angiogenesis Inhibitors Product Portfolio Table 120. Genentech Recent Development Table 121. Fuji Film Kyowa Kirin Biologics Company Information Table 122. Fuji Film Kyowa Kirin Biologics Business Overview Table 123. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio Table 125. Fuji Film Kyowa Kirin Biologics Recent Development Table 126. Five Prime Therapeutics Company Information Table 127. Five Prime Therapeutics Business Overview Table 128. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio Table 130. Five Prime Therapeutics Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Cancer Angiogenesis Inhibitors Distributors List Table 134. Cancer Angiogenesis Inhibitors Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Cancer Angiogenesis Inhibitors Product Image Figure 2. Global Cancer Angiogenesis Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Angiogenesis Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Angiogenesis Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Cancer Angiogenesis Inhibitors Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Angiogenesis Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oncogene Targeted Therapy Image Figure 9. Matrix Degrading & Remodeling Targeted Therapy Image Figure 10. VEGF Targeted Therapy Image Figure 11. FGF Targeted Therapies Image Figure 12. Others Image Figure 13. Global Cancer Angiogenesis Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Cancer Angiogenesis Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2032) Figure 16. Global Cancer Angiogenesis Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Cancer Angiogenesis Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2032) Figure 19. Ocular Neovascularization Image Figure 20. Interferon Alpha-2α Image Figure 21. Cancer Image Figure 22. Global Cancer Angiogenesis Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Cancer Angiogenesis Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2032) Figure 25. Global Cancer Angiogenesis Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Cancer Angiogenesis Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2032) Figure 28. North America Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Cancer Angiogenesis Inhibitors Sales Market Share by Country (2021-2032) Figure 30. U.S. Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Cancer Angiogenesis Inhibitors Sales Market Share by Country (2021-2032) Figure 35. Germany Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Cancer Angiogenesis Inhibitors Sales Market Share by Country (2021-2032) Figure 42. China Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales Market Share by Country (2021-2032) Figure 50. Brazil Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Cancer Angiogenesis Inhibitors Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Cancer Angiogenesis Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Figure 61. North America Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. Europe Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Cancer Angiogenesis Inhibitors Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Cancer Angiogenesis Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Oncogene Targeted Therapy
  • Matrix Degrading & Remodeling Targeted Therapy
  • VEGF Targeted Therapy
  • FGF Targeted Therapies
  • Others
Applications
  • Ocular Neovascularization
  • Interferon Alpha-2α
  • Cancer
Companies covered
  • Novartis
  • Neumedicines
  • Marsala Biotech
  • Mabtech
  • Levolta Pharmaceuticals
  • Kyowa Hakko Kirin
  • Intas Pharmaceuticals
  • ImClone Systems
  • Hetero Drugs
  • Genexine
  • Genentech
  • Fuji Film Kyowa Kirin Biologics
  • Five Prime Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Angiogenesis Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Angiogenesis Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Angiogenesis Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Angiogenesis Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Angiogenesis Inhibitors Market Dynamics
  1. 2.1 Cancer Angiogenesis Inhibitors Industry Trends
  2. 2.2 Cancer Angiogenesis Inhibitors Industry Drivers
  3. 2.3 Cancer Angiogenesis Inhibitors Industry Opportunities and Challenges
  4. 2.4 Cancer Angiogenesis Inhibitors Industry Restraints
3 Cancer Angiogenesis Inhibitors Market by Manufacturers
  1. 3.1 Global Cancer Angiogenesis Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Angiogenesis Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Angiogenesis Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Angiogenesis Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Angiogenesis Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Angiogenesis Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Angiogenesis Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Angiogenesis Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Angiogenesis Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Angiogenesis Inhibitors Tier 1, Tier 2, and Tier 3
4 Cancer Angiogenesis Inhibitors Market by Type
  1. 4.1 Cancer Angiogenesis Inhibitors Type Introduction
  2. 4.1.1 Oncogene Targeted Therapy
  3. 4.1.2 Matrix Degrading & Remodeling Targeted Therapy
  4. 4.1.3 VEGF Targeted Therapy
  5. 4.1.4 FGF Targeted Therapies
  6. 4.1.5 Others
  7. 4.2 Global Cancer Angiogenesis Inhibitors Sales by Type
  8. 4.2.1 Global Cancer Angiogenesis Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Cancer Angiogenesis Inhibitors Sales by Type (2021-2032)
  10. 4.2.3 Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2021-2032)
  11. 4.3 Global Cancer Angiogenesis Inhibitors Revenue by Type
  12. 4.3.1 Global Cancer Angiogenesis Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Cancer Angiogenesis Inhibitors Revenue by Type (2021-2032)
  14. 4.3.3 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Type (2021-2032)
5 Cancer Angiogenesis Inhibitors Market by Application
  1. 5.1 Cancer Angiogenesis Inhibitors Application Introduction
  2. 5.1.1 Ocular Neovascularization
  3. 5.1.2 Interferon Alpha-2α
  4. 5.1.3 Cancer
  5. 5.2 Global Cancer Angiogenesis Inhibitors Sales by Application
  6. 5.2.1 Global Cancer Angiogenesis Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Angiogenesis Inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Cancer Angiogenesis Inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cancer Angiogenesis Inhibitors Revenue by Application
  10. 5.3.1 Global Cancer Angiogenesis Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Angiogenesis Inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Cancer Angiogenesis Inhibitors Sales by Region
  1. 6.1 Global Cancer Angiogenesis Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Angiogenesis Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Angiogenesis Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Angiogenesis Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Angiogenesis Inhibitors Revenue by Region
  1. 7.1 Global Cancer Angiogenesis Inhibitors Revenue by Region
  2. 7.1.1 Global Cancer Angiogenesis Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Angiogenesis Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Angiogenesis Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Angiogenesis Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Angiogenesis Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Angiogenesis Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Angiogenesis Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Angiogenesis Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Cancer Angiogenesis Inhibitors Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Neumedicines
  8. 8.2.1 Neumedicines Company Information
  9. 8.2.2 Neumedicines Business Overview
  10. 8.2.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Neumedicines Cancer Angiogenesis Inhibitors Product Portfolio
  12. 8.2.5 Neumedicines Recent Developments
  13. 8.3 Marsala Biotech
  14. 8.3.1 Marsala Biotech Company Information
  15. 8.3.2 Marsala Biotech Business Overview
  16. 8.3.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolio
  18. 8.3.5 Marsala Biotech Recent Developments
  19. 8.4 Mabtech
  20. 8.4.1 Mabtech Company Information
  21. 8.4.2 Mabtech Business Overview
  22. 8.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mabtech Cancer Angiogenesis Inhibitors Product Portfolio
  24. 8.4.5 Mabtech Recent Developments
  25. 8.5 Levolta Pharmaceuticals
  26. 8.5.1 Levolta Pharmaceuticals Company Information
  27. 8.5.2 Levolta Pharmaceuticals Business Overview
  28. 8.5.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
  30. 8.5.5 Levolta Pharmaceuticals Recent Developments
  31. 8.6 Kyowa Hakko Kirin
  32. 8.6.1 Kyowa Hakko Kirin Company Information
  33. 8.6.2 Kyowa Hakko Kirin Business Overview
  34. 8.6.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolio
  36. 8.6.5 Kyowa Hakko Kirin Recent Developments
  37. 8.7 Intas Pharmaceuticals
  38. 8.7.1 Intas Pharmaceuticals Company Information
  39. 8.7.2 Intas Pharmaceuticals Business Overview
  40. 8.7.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolio
  42. 8.7.5 Intas Pharmaceuticals Recent Developments
  43. 8.8 ImClone Systems
  44. 8.8.1 ImClone Systems Company Information
  45. 8.8.2 ImClone Systems Business Overview
  46. 8.8.3 ImClone Systems Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolio
  48. 8.8.5 ImClone Systems Recent Developments
  49. 8.9 Hetero Drugs
  50. 8.9.1 Hetero Drugs Company Information
  51. 8.9.2 Hetero Drugs Business Overview
  52. 8.9.3 Hetero Drugs Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolio
  54. 8.9.5 Hetero Drugs Recent Developments
  55. 8.10 Genexine
  56. 8.10.1 Genexine Company Information
  57. 8.10.2 Genexine Business Overview
  58. 8.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Genexine Cancer Angiogenesis Inhibitors Product Portfolio
  60. 8.10.5 Genexine Recent Developments
  61. 8.11 Genentech
  62. 8.11.1 Genentech Company Information
  63. 8.11.2 Genentech Business Overview
  64. 8.11.3 Genentech Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Genentech Cancer Angiogenesis Inhibitors Product Portfolio
  66. 8.11.5 Genentech Recent Developments
  67. 8.12 Fuji Film Kyowa Kirin Biologics
  68. 8.12.1 Fuji Film Kyowa Kirin Biologics Company Information
  69. 8.12.2 Fuji Film Kyowa Kirin Biologics Business Overview
  70. 8.12.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolio
  72. 8.12.5 Fuji Film Kyowa Kirin Biologics Recent Developments
  73. 8.13 Five Prime Therapeutics
  74. 8.13.1 Five Prime Therapeutics Company Information
  75. 8.13.2 Five Prime Therapeutics Business Overview
  76. 8.13.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolio
  78. 8.13.5 Five Prime Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Angiogenesis Inhibitors Value Chain Analysis
  2. 9.1.1 Cancer Angiogenesis Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Angiogenesis Inhibitors Production Mode & Process
  6. 9.2 Cancer Angiogenesis Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Angiogenesis Inhibitors Distributors
  9. 9.2.3 Cancer Angiogenesis Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst